Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention

被引：55

作者：

Tyagi, Preeta

Chu, Edward

Nadler, Eric

Jain, Vinay K.

机构：

来源：

CLINICAL COLORECTAL CANCER | 2005年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1533-0028(11)70190-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：245 / 246

页数：2

共 6 条

[1] Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells [J].

Hentosh, P ;

Yuh, SH ;

Elson, CE ;

Peffley, DM .

MOLECULAR CARCINOGENESIS, 2001, 32 (03) :154-166

[2] Statins and the risk of colorectal cancer [J].

Poynter, JN ;

Gruber, SB ;

Higgins, PDR ;

Almog, R ;

Bonner, JD ;

Rennert, HS ;

Low, M ;

Greenson, JK ;

Rennert, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (21) :2184-2192

[3]

POYNTER JN, 2004, 40 ANN M AM SOC CLIN

[4] Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis [J].

Rao, CV ;

Newmark, HL ;

Reddy, BS .

CANCER DETECTION AND PREVENTION, 2002, 26 (06) :419-425

[5]

Wong WWL, 2001, CLIN CANCER RES, V7, P2067

[6] Following positive epidemiologic studies, statins to enter clinical trials for cancer prevention [J].

Zielinski, SL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1172-1173

← 1 →